Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451639 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL790606 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL873924 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL3067126 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL8798470 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| Methane SCHEMBL268170 | 0.98 | CA1 (0.57) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL14748064 | 0.98 | CA1 (0.61) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL8805427 | 0.98 | CA1 (0.61) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL874007 | 0.91 | — | — | |
| Ethylene Glycol SCHEMBL9698302 | 0.84 | CA1 (0.44) | CA1ACE2FFAR1FFAR4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399200-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | Mitsubishi Gas Chemical Company, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023038156-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-03-16 | — | — | WO | disclosed |
| WO-2020079225-A1 | POLYCYCLIC COMPOUNDS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020080558-A1 | POLYCYCLIC COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-04-23 | — | — | WO | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2001021575-A1 | ANTI-INFLAMMATORY NITRO- AND THIA- FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021172-A1 | ANTI-CANCER NITRO- AND THIA-FATTY ACIDS | WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE (AU) | 2001-03-29 | — | — | WO | disclosed |
| US-6187814-B1 | BY TOPICALLY AN FARNESOID X-ACTIVATED RECEPTOR (FXR) ACTIVATOR SELECTED FROM FARNESAL, ALKYL FARNESYL ETHER, ALKYL FARNESOATE, AND 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID, ALKYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-13 | — | — | US | disclosed |
| US-6184215-B1 | TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-06 | — | — | US | disclosed |
| US-6060515-A | TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0460950-B1 | Radicicol derivatives, their preparation and their anti-tumour activity | SANKYO CO (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | CA1 4809/4885ACE2 797/4885FFAR1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.